Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of Novartis Meningococcal B Vaccine (OMV-based) in healthy adolescents aged 11-17, with formulations from two …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Novartis Meningococcal B Vaccine (OMV-based) (Meningococcal B vaccine (outer membrane vesicle-based))

Snippet

Sponsor: Novartis | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2015-02-20